Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLGW) Operating Expenses (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Operating Expenses for 2 consecutive years, with $1.3 million as the latest value for Q4 2017.

  • Quarterly Operating Expenses fell 57.92% to $1.3 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2017, down 87.13% year-over-year, with the annual reading at $3.2 million for FY2025, 23.33% down from the prior year.
  • Operating Expenses for Q4 2017 was $1.3 million at Bone Biologics, up from $1.1 million in the prior quarter.
  • The five-year high for Operating Expenses was $9.1 million in Q1 2016, with the low at -$2.0 million in Q2 2017.